| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3798209 | Medicina Clínica | 2014 | 7 Pages |
Abstract
The dual antiplatelet therapy with acetylsalicylic acid and clopidogrel has been the mainstay of both acute and chronic phase coronary artery disease, reducing importantly the risk of adverse events. Despite a correct compliance, a non-negligible rate of adverse events still happens. New compounds, with improved properties, are now clinically available (such as prasugrel or ticagrelor) or under advanced development. The aim of the present review is the description of these new compounds, particularly prasugrel and ticagrelor.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Antonio Tello-Montoliu, Eva Jover, Mariano Valdés,